Old and New Adjunctive Therapies in Celiac Disease and Refractory Celiac Disease: A Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Aug 26

PMID 37628981

Authors

Marco Valvano

Stefano Fabiani

Sabrina Monaco

Mauro Calabro

Antonio Mancusi

Sara Frassino

Claudia Rolandi

Marta Mosca

Susanna Faenza

Emanuele Sgamma

Nicola Cesaro

Giovanni Latella

Affiliations

Soon will be listed here.

Abstract

Celiac disease (CD) is a chronic enteropathy caused by the ingestion of gluten in a genetically susceptible individual. Currently, a gluten-free diet (GFD) is the only recommended treatment. However, unintentional gluten ingestion or a persistent villous atrophy with malabsorption (regardless of a strict GFD) as in the case of Refractory Celiac Disease (RCD) represents a major issue. In this review, we have analysed and discussed data from both randomized controlled trials and observational studies concerning adjunctive therapies as well as novel therapies for the treatment of CD and RCD. The literature search was carried out through Medline and Scopus. In total, 2268 articles have been identified and 49 were included in this review (36 studies resulting from the search strategy and 13 from other sources). Today, GFD remains the only effective treatment, although steroids, mesalamine, and more recently biological therapies have found space in the complex management of RCD. Currently, studies evaluating the effectiveness of novel therapies are still limited and preliminary results have been controversial.

Citing Articles

Persistence of anemia in patients with Celiac disease despite a gluten free diet: a retrospective study.

Marco V, Valvano M, Giansante C, Chiara G, Vinci A, Antonio V BMC Gastroenterol. 2025; 25(1):128.

PMID: 40033207 PMC: 11877744. DOI: 10.1186/s12876-025-03712-6.

Refractory Celiac Disease: What the Gastroenterologist Should Know.

Verdelho Machado M Int J Mol Sci. 2024; 25(19).

PMID: 39408713 PMC: 11477276. DOI: 10.3390/ijms251910383.

Unraveling the Immunopathological Landscape of Celiac Disease: A Comprehensive Review.

Patt Y, Lahat A, David P, Patt C, Eyade R, Sharif K Int J Mol Sci. 2023; 24(20).

PMID: 37895160 PMC: 10607730. DOI: 10.3390/ijms242015482.

References

Singh P, Arora A, Strand T, Leffler D, Catassi C, Green P . Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018; 16(6):823-836.e2. DOI: 10.1016/j.cgh.2017.06.037. View

Olivares M, Castillejo G, Varea V, Sanz Y . Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br J Nutr. 2014; 112(1):30-40. DOI: 10.1017/S0007114514000609. View

Syage J, Green P, Khosla C, Adelman D, Sealey-Voyksner J, Murray J . Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet. GastroHep. 2020; 1(6):293-301. PMC: 7169937. DOI: 10.1002/ygh2.371. View

Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F . Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. J Clin Gastroenterol. 2018; 53(3):e117-e125. PMC: 6382041. DOI: 10.1097/MCG.0000000000001023. View

Daveson A, Ee H, Andrews J, King T, Goldstein K, Dzuris J . Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind,.... EBioMedicine. 2017; 26:78-90. PMC: 5832635. DOI: 10.1016/j.ebiom.2017.11.018. View

Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders D, Cellier C . European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019; 7(5):583-613. PMC: 6545713. DOI: 10.1177/2050640619844125. View

Wild D, Robins G, Burley V, Howdle P . Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. Aliment Pharmacol Ther. 2010; 32(4):573-81. DOI: 10.1111/j.1365-2036.2010.04386.x. View

Al-Toma A, Visser O, van Roessel H, von Blomberg B, Verbeek W, Scholten P . Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood. 2006; 109(5):2243-9. DOI: 10.1182/blood-2006-08-042820. View

Pinto-Sanchez M, Smecuol E, Temprano M, Sugai E, Gonzalez A, Moreno M . Bifidobacterium infantis NLS Super Strain Reduces the Expression of α-Defensin-5, a Marker of Innate Immunity, in the Mucosa of Active Celiac Disease Patients. J Clin Gastroenterol. 2016; 51(9):814-817. DOI: 10.1097/MCG.0000000000000687. View

10.

Tack G, Verbeek W, Al-Toma A, Kuik D, Schreurs M, Visser O . Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol. 2011; 17(4):506-13. PMC: 3027018. DOI: 10.3748/wjg.v17.i4.506. View

11.

Green P, Paski S, Ko C, Rubio-Tapia A . AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review. Gastroenterology. 2022; 163(5):1461-1469. DOI: 10.1053/j.gastro.2022.07.086. View

12.

Gopalakrishnan S, Durai M, Kitchens K, Tamiz A, Somerville R, Ginski M . Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012; 35(1):86-94. DOI: 10.1016/j.peptides.2012.02.015. View

13.

Costantino G, Della Torre A, Lo Presti M, Caruso R, Mazzon E, Fries W . Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis. 2007; 40(1):74-7. DOI: 10.1016/j.dld.2006.10.017. View

14.

Green P, Lebwohl B . Mesalamine for refractory celiac disease: an old medicine for a new disease. J Clin Gastroenterol. 2010; 45(1):1-3. DOI: 10.1097/MCG.0b013e3181fb4535. View

15.

Abbas A, Shahab T, Sherwani R, Alam S . Addition of a Short Course of Prednisolone to a Gluten-Free Diet vs. Gluten-Free Diet Alone in Recovery of Celiac Disease: A Pilot Randomized Controlled Trial. Cureus. 2018; 10(1):e2118. PMC: 5873829. DOI: 10.7759/cureus.2118. View

16.

Yokoyama S, Perera P, Waldmann T, Hiroi T, Perera L . Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol. 2012; 33(3):586-94. PMC: 3594487. DOI: 10.1007/s10875-012-9849-y. View

17.

Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L . Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol Hepatol. 2019; 4(12):960-970. DOI: 10.1016/S2468-1253(19)30265-1. View

18.

Rubio-Tapia A, Murray J . Classification and management of refractory coeliac disease. Gut. 2010; 59(4):547-57. PMC: 2861306. DOI: 10.1136/gut.2009.195131. View

19.

Gillett H, Arnott I, McIntyre M, Campbell S, Dahele A, Priest M . Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology. 2002; 122(3):800-5. DOI: 10.1053/gast.2002.31874. View

20.

Newnham E, Clayton-Chubb D, Nagarethinam M, Hosking P, Gibson P . Randomised clinical trial: adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease. Aliment Pharmacol Ther. 2021; 54(4):419-428. DOI: 10.1111/apt.16446. View